Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases

Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases

To evaluate engraftment and toxicity of a reduced intensity preparative regimen for patients who receive a matched related or unrelated donor allogeneic stem cell transplant (ASCT) for malignant hematological diseases

Primary Endpoints:

1. Engraftment of donor cells
2. Regimen related toxicities

Secondary Endpoints:

1. Disease-free survival
2. Overall survival

Inclusion Criteria:

• Performance status 0-2
• Ejection fraction > 30%
• AST/ALT and bilirubin not > 4 times normal
• Creatinine clearance greater than 70 ml/min.
• FEV1 greater than 1.0 and diffusion capacity greater than 40%
• Age 18-75 years
• Patients must be at high risk for conventional regimen related toxicity
• Malignant hematologic disease that would otherwise be considered treatable with ASCT

Exclusion Criteria:

• Does not meet the above Inclusion criteria